FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Report a Drug Shortage | Contact Us | FAQ | Background Info | Get Email Alerts | Download Current Drug Shortages

Start Over | Back to Previous Screen

Dacarbazine Injection
Status: Currently in Shortage
»Date first posted: 10/20/2021
»Therapeutic Categories: Oncology

Expand all

Fresenius Kabi USA, LLC (Revised 03/10/2023)

Company Contact Information:
888-386-1300

Presentation	Availability and Estimated Shortage Duration	Related Information	Shortage Reason (per FDASIA)
100 mg per vial, Single Dose Amber Vial (NDC 63323-127-10)	Available		Available
200 mg per vial, Single Dose Amber Vial (NDC 63323-128-20)	Backordered. Next release March 2023.		Manufacturing delay

Hikma Pharmaceuticals USA, Inc. (formerly West-Ward) (Revised 10/13/2022)

Company Contact Information:
800-631-2174

Presentation	Availability and Estimated Shortage Duration	Related Information	Shortage Reason (per FDASIA)
200 mg/vial (NDC 0143-9245-10)	Inventory is currently available.	Additional lots will be scheduled for manufacturing. Product will be made available as it is released.	Demand increase for the drug

Teva Pharmaceuticals (Revised 01/09/2023)

Company Contact Information:
800-545-8800

Presentation	Availability and Estimated Shortage Duration	Related Information	Shortage Reason (per FDASIA)
200 mg 10x20mL (NDC 00703-5075-03)	Unavailable	Recovery TBD	Demand increase for the drug
200 mg 1x20mL (NDC 00703-5075-01)	Unavailable	Recovery TBD	Demand increase for the drug